Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Rahmani NE. et al, (2021), Blood Cancer Journal, 11

The protective effects of prolactin on brain injury.

Yousefvand S. et al, (2020), Life Sci, 263

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.

Singh S. et al, (2020), Leukemia, 34, 2525 - 2530

Application of induced pluripotent stem cell technology for the investigation of hematological disorders.

Dolatshad H. et al, (2019), Adv Biol Regul, 71, 19 - 33

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A. et al, (2018), Blood, 132, 1225 - 1240

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.

Naeimi Kararoudi M. et al, (2018), J Vis Exp

Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation.

Naeimi Kararoudi M. et al, (2018), Front Immunol, 9

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH. et al, (2017), J Clin Invest, 127, 2206 - 2221

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

Dolatshad H. et al, (2016), Leukemia, 30, 2322 - 2331

Application of genome editing technologies to the study and treatment of hematological disease.

Pellagatti A. et al, (2016), Adv Biol Regul, 60, 122 - 134

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.

Yip BH. et al, (2016), Curr Pharm Des, 22, 2333 - 2344

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.

Valletta S. et al, (2015), Oncotarget, 6, 44061 - 44071

Lineage-Specific Aberrant mRNA Splicing By U2AF1 Mutation Alters Erythroid and Granulomonocytic Differentiation

Yip BH. et al, (2015), BLOOD, 126

A versatile transgenic allele for mouse overexpression studies.

Dolatshad H. et al, (2015), Mamm Genome, 26, 598 - 608

A versatile transgenic allele for mouse overexpression studies

Dolatshad H. et al, (2015), Mammalian Genome, 26, 598 - 608

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Dolatshad H. et al, (2015), Leukemia, 29

Application of CRISPR/Cas9 genome editing to the study and treatment of disease.

Pellagatti A. et al, (2015), Arch Toxicol, 89, 1023 - 1034

CORRECTION OF MUTATIONS OF THE EPIGENETIC MODIFIER ASXL1 IN MYELOID LEUKEMIA CELLS BY CRISPR/CAS9 GENOME EDITING

Valletta S. et al, (2015), HAEMATOLOGICA, 100, 169 - 169

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Dolatshad H. et al, (2015), Leukemia, 29, 1092 - 1103

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung M. et al, (2015), Nat Commun, 6

Load More

Include forthcoming?